Overall survival results from the LUX-Lung 8 trial comparing two EGFR-directed treatments, Gilotrif (afatinib) and Tarceva (erlotinib), in patients with advanced squamous cell carcinoma of the lung progressing after treatment with first-line chemotherapy, demonstrated that treatment with Gilotrif significantly reduced the risk of death by 19 percent, extending the survival of patients to a median of 7.9 months compared to 6.8 months on Tarceva.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
